Teva to Present at the Credit Suisse 2011 Healthcare Conference

JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) will host a live audio webcast at the Credit Suisse 2011 Healthcare Conference with Eyal Desheh, Chief Financial Officer, Teva Pharmaceutical Industries Ltd., presenting on Thursday, November 10, 2011 in Arizona.

What:

    Teva Presentation at the Credit Suisse 2011 Healthcare Conference
 

Who:

Eyal Desheh, CFO, Teva Pharmaceutical Industries Ltd.
 

When:

Thursday, November 10, 2011 at 3:30 pm EST
 

Where:

http://cc.talkpoint.com/cred001/110911a_ah/?entity=12_SH4JBPM

 

How:

Live over the Internet – log on to the Web at the address above and register for the event (approx. 10 minutes before).  An archive of the webcast will be available on Teva’s website.

About Teva

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,300 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 45,000 people around the world and reached $16.1 billion in net sales in 2010.



CONTACT:

IR:
Teva Pharmaceutical Industries Ltd.
Elana Holzman, 972 (3) 926-7554
or
Teva North America
Kevin C. Mannix, 215-591-8912
or
PR:
Teva Pharmaceutical Industries Ltd.
Yossi Koren, 972 (3) 926-7687
or
Teva North America
Denise Bradley, 215-591-8974

KEYWORDS:   United States  North America  New York  Middle East  Israel

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Suggested Articles

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…